Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: schadenfreude who wrote (7602)	10/30/1998 5:08:00 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

IMO, No. And No. Glasgow scale was used to determine seriousness of the illness. Meaning that even without the LBP diagnostic tool there was a tool for measuring severity of this disease. Don't mean the new diagnostic tool would not be of use here also but just that given the specific characteristics of meningococcal infection and the years of use of this scale, it seems prognosis is less unclear than in other sepsis infections. Opinion of one without any medical nor scientific background, so take it for what it's worth. DSMB meets just prior of end of trial. There are some benefits of a recommendation for an early halt even at that point. But obviously I don't know what they will recommend.

To: schadenfreude who wrote (7602)	10/31/1998 12:13:00 AM
From: Robert K.	Read Replies (1) \| Respond to of 17367

Otaku, what do you think they have been using in their trials? How do you think they determined its a marker? Yes, they have been using it in their trials as I understand it. And LBP as diagnostic is peanuts compared to modified lbp as a drug. Very few people understand this. LBP based therapies may equal or even exceed the potential of bpi based therapies IMO. And IMO bpi based therapies have the "potential" to "perhaps" vastly exceed all expectations. Which brings me to trauma, getting darn close to 400 in. They wont just be looking at safety IMO. And how about liver. And chew on this and this is a truly wild one. It seems high cd14 levels are prognostic for poor outcome in HIV. Will the bpi/lbp connection fit in here? Perhaps not, but one never does know. Seems bpi has potential across the spectrum of most pathogens, what the heck. One never knows.Last note. xoma has been quietly accumulating lbp patents. All IMO, all disclaimers always apply. Mostly speculation on my part with little basis other than guesswork. Value as worthless. Never invest based on what I say, etc......